Instrument NameMerck & CompanyInstrument Symbol(MRK-N)

Instrument ExchangeNYSE

All 3 stocks are high on my watchlist.

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

KIRKLAND, QC , Nov. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada , announced that Canada's Drug Agency (CDA) has recommended WINREVAIR ® (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.

/CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR®...

If you're patient, these businesses have a lot of promising projects in the works.

These stocks have seen better days but investors shouldn't count them out in the long run.

These stocks near 52-week lows could be ready to rebound.

After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.

This pharmaceutical giant's Q3 numbers came in ahead of Street estimates.

Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway.

Wall Street's bearish take on this proven innovator may not be warranted.

The Dow finished October down slightly. Should you buy any of these blue chips?

The price could be right for these stocks.

These are the kinds of stocks that can allow investors to sleep easy at night.

The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.

MRK earnings call for the period ending September 30, 2024.

These dividend stocks can be excellent options for buy-and-hold investors.

December S&P 500 E-Mini futures (ESZ24) are down -0.77%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -1.09% this morning as investors digested quarterly earnings reports from Microsoft and Meta as well as robust U.S. economic data that muddied the outlook for Federal Reserve rate cuts.

December S&P 500 E-Mini futures (ESZ24) are up +0.37%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.48% this morning as investors looked ahead to earnings reports from some of the biggest tech heavyweights as well as key economic data, including a payrolls report, the Fed’s favorite inflation gauge, and the first estimate of third-quarter GDP.

There's a lot to like here.

After more than doubling in the past year, is this clinical-stage biotech stock still a buy?

These stocks are trading at less than 15 times their expected future profits.

The shares have experienced a pullback in the past couple of weeks.

Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.

There's doubtlessly some coming uncertainty for both, but the prices are right.